rosiglitazone new england journal of medicine

#Rosiglitazone new england journal of medicine professional

#Rosiglitazone new england journal of medicine professional

In fiscal year 2005–06 the association invested over $543 million in research, professional and public education, advocacy and community service programs to help all Americans live longer, healthier lives. 3 killers, and all other cardiovascular diseases claim over 870,000 lives a year. Visit the American Diabetes Association at or call 1-800-DIABETES (1-80).įounded in 1924, the American Heart Association today is the nation’s oldest and largest voluntary health organization dedicated to reducing disability and death from diseases of the heart and stroke. The Association's commitment to research is reflected through its scientific meetings education and provider recognition programs and its Research Foundation and Nationwide Research Program, which fund breakthrough studies looking into the cure, prevention, and treatment of diabetes and its complications. Founded in 1940, the Association's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. The American Diabetes Association is the nation’s premier voluntary health organization supporting diabetes research, information and advocacy. The ACC provides professional education and operates national registries for the measurement and improvement of quality care. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The College is a 34,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The American College of Cardiology is leading the way to optimal cardiovascular care and disease prevention. Information from the FDA for rosiglitazone can be found at: Ībout the American College of Cardiology: If you have diabetes, it is very important to control your blood glucose, blood pressure and cholesterol levels. The most life-threatening consequences of diabetes are heart disease and stroke, which strike people with diabetes more than twice as often as they do others. The treatment of diabetes should be a team approach, with health care providers and patients working together to ensure patient education and empowerment. It is very important to prevent diabetes when possible and to effectively treat it when it is present. Further research will be needed in this area to provide conclusive evidence. Patients should not stop taking any prescribed medications without first discussing the issue with their health care provider. In the meantime, patients using this drug should talk to their health care provider to determine the most appropriate course of action. As estimated here, the overall level of the risk associated with rosiglitazone appears to be small, but nonetheless one that must be considered carefully. Today the New England Journal of Medicine published an article entitled, “Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes.” The conclusions of this analysis of previous studies of rosiglitazone (brand name, Avandia) suggest that this oral agent used to treat type 2 diabetes may be associated with increased risk of heart attack and death from cardiovascular causes.Īccording to ACC, ADA and AHA, this study deserves serious thought and follow-up.